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nificantly lower all-cause mortality rate (14.4% vs 51.7%, p< 0.001), fewer total hos-
pitalizations (p< 0.001) and fewer hospitalizations due to cardiovascular problems 
(p< 0.001) were observed in patients discharged with statins. LDL-C goal attainment 
of < 100 mg/dL (2.6 mmol/L) resulted in a significant reduction in mortality (10.8% vs 
24.2%, p= 0.001), but not for goal attainment of < 70 mg/dL (1.8 mmol/L). Significant 
difference in survival existed only when LDL-C cut-off values were above 92 mg/dL 
(2.4 mmol/L). ConClusions: This study revealed a J-curve phenomenon in ACS 
patients of Hong Kong. Further research should be conducted to assess the necessity 
of aggressive LDL-C reduction to < 70 mg/dL (1.8 mmol/L).
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objeCtives: The New Cooperative Medical Scheme (NCMS) which aims to reduce 
the risk of catastrophic health spending for rural residents has substantially 
improved health care access and utilization in China. However, cost containment 
and provider incentive remains a huge challenge, which has been particularly acute 
in poorer rural areas, such as the North-west. Over the past years, several coun-
ties in Gansu province have introduced a variety of provider payment reforms, 
shifting from the traditional Fee-for-Service to case-based, global budget  and/
or per-diem  methods. This study provides the first impact evaluation of these 
reforms. Methods: Using a quasi-experimental design, we collected NCMS claims 
data from 2008 to 2013 in three counties. A difference-in-difference analysis is per-
formed to take advantage of the variation in provider payment methods imple-
mented at different years across the counties. We also control for patients’ age, 
gender and diagnosis as well as demographic factor of each county in estimating the 
effects of payment reform on cost (measured by inpatient health care expenditure) 
and quality (measured by readmission rate). In addition to the quantitative analysis, 
we conduct key informant interviews with policymakers, hospital administrators, 
and medical professionals to better understand the design and implementation 
issues involved in the reform process. Results: Preliminary data analysis indicates 
that in one county, the provider payment reform is associated with 9.8% drop in total 
health care expenditure per admission. Length of stay fell by 4.9% as a result too.  
However, other factors such as changes in the demand-side reimbursement rate 
may also influence the outcomes. Differences in local infrastructure and technical 
capacity have led to the same payment method implemented differently at the 
county level. ConClusions: Provider payment reform in rural China can be an 
effective way to control health expenditure. However, more technical guidance on 
designing the right payment is needed for future reforms.
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objeCtives: Single pill combinations (SPC) are associated with improved adherence 
and persistence in hypertensive (HTN) populations. High adherence and persistence 
can provide medical benefit for patients and reduce the total health care utiliza-
tion and costs. This study investigated if Exforge HCT is associated with reduced 
health care utilization and costs during the 12 months follow up period in adult 
hypertensive (HTN) patients adherent to treatment. Methods: A retrospective 
cohort study was conducted including adult (18 yrs. or older) HTN patients covered 
by commercial and Medicare Supplemental insurance in the Truven MarketScan 
database with an HTN diagnosis between October 2009 and December 2011. At 
least two filled prescriptions for Exforge HCT or two periods of minimum 15 days 
of concurrent use of amlodipine, valsartan and hydrochlorothiazide (FC cohort), 
and at least 80% Medication Possession Ratio(MPR) were required. Chi-Square tests 
and independent sample t-tests were used after propensity score matching (PSM) 
(absolute standardized differences (ASM) < 0.1) using demographics, comorbidi-
ties, pre-index HRU, pre-index costs and valsartan initial dose. Results: Adherent 
Exforge HCT patients (N= 6,004) had better outcomes compared to adherent FC 
patients (N= 1,084) in the 12 months follow up period: less all cause hospitalization 
(9.2% vs 16.6%, p< 0.05; Mean 0.1 vs 0.2, p< 0.0001), less all cause ER visits(19.0% vs 
29.3%, p< 0.05; Mean 0.3 vs 0.6, p< 0.0001), less HTN specific ER visits(7.0% vs 12.0%, 
p< 0.05; Mean 0.1 vs 0.2, p< 0.0001), less total medical service cost(7247$ vs $10370, 
p< 0.0001), less total prescription drug costs(3926$ vs $5350, p< 0.0001) and less total 
health care costs($11173 vs $15720, p< 0.0001). After applied PSM, adherent Exforge 
HCT patients still had lower proportion of all cause hospitalization, all cause ER 
visit and less number of all prescriptions, p< 0.05. ConClusions: Real-world data 
indicate that Exforge HCT is associated with less health care utilization and costs 
compared to amlodipine/valsartan/hydrochlorothiazide FC among patients with 
adherent treatment of HTN.
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objeCtives: Generic entry of pharmaceuticals in Australia triggers a price reduc-
tion of 16%, followed by further reductions via a process called ‘Price Disclosure’ 
(PD).  Significant price reductions for standard of care (SOC) derived through PD 
groups. ConClusions: No statistically significant difference in the effectiveness 
of oral Ibuprofen and oral Indomethacin compared to the intravenous NSAIDs with 
similar adverse outcome were observed. Oral formulations of Indomethacin and 
Ibuprofen might be considered as an alternative pharmacologic closure in PDA 
treatment for the NICU settings where intravenous NSAIDs is unavailable.
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objeCtives: To evaluate the management of ischaemic stroke (IS) patients enrolled 
in the Japan Stroke Databank (JSD) from 2000 to 2007. Methods: JSD is an obser-
vational registry of patients who experienced a stroke event, collecting patient 
information provided by over 80 Japanese hospital departments. Data included 
demographics, time to admission, medical history, stroke type diagnosis, imaging, 
treatment,  Japan Stroke Scale (JSS), NIH Stroke Scale (NIHSS) and the modified 
Rankin Scale (m-RS). Logistic regression model was used to identify predictors of 
m-RS 0-1 at discharge. Results: Of the 47,782 stroke patients, when excluding for 
transient ischemic attack (TIA) cases, 15,282 (32%) were ischaemic stroke cases with 
NIHSS evaluation at hospitalization and at discharge and with m-RS assessment 
at discharge. Average age was 69.7 years (±10.6) and 64% were males. Patients who 
were admitted to hospital at a later time window from onset had a lower m-RS score 
(0-1) at admission (12%, 13%, 15% and 17% for patients admitted at 0-3, 3-4.5, 4.5-8 
and 8-24 hours , respectively). However, patients admitted at later time-windows 
had worse disability at discharge (within patients admitted with m-RS 0-1, 53% vs. 
48% had m-RS 0 at discharge depending if admitted before or after 3 hours after 
onset). 57% of patients arrived after 3 hours and only 5.8% received thrombolytic 
treatment (2.1% received alteplase and the remaining received urokinase). Non-
significant severity at baseline and alteplase with edaravone lowered the odds of 
severity at discharge. ConClusions: This study demonstrates that despite the 
availabilities of therapies for acute ischemic stroke there is still a high unmet need 
to reduce severity at discharge for these patients as only 5.8 % of patients receive 
thrombolytic therapy.
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objeCtives: As the international guidance for lipid control has evolved, the 
National Health Insurance Administration (NHIA) in Taiwan was requested to 
modify the current reimbursement criteria for initiation of lipid-lowering treatment. 
The study aims to evaluate the cost-effectiveness and the budget impact of the 
newly proposed reimbursement criteria on lipid-lowering drug from the NHIA’s 
viewpoint with a focus on the change of statins usage. Methods: In the new cri-
teria, the cut-off points of low-density lipoprotein cholesterol (LDL-C) and total 
cholesterol for initiating lipid-lowering therapy for patients having diabetes or previ-
ous heart diseases (high risk group) have been lowered. A Markov decision model 
was constructed to examine the cost-effectiveness of the new criteria compared 
with the original ones. The efficacy of statins on coronary heart diseases (CHD) 
and stroke was obtained from the literature. The numbers of subjects who may be 
affected by these criteria changes and the LDL-C specific disease transition prob-
abilities were obtained from a population-based survey conducted by the Taiwan 
Health Promotion Administration (HPA). Medical costs were derived from the NHI 
data. Both costs and health outcomes were discounted at 3%. The corresponding 
financial impact on NHI expenditure was also estimated. Results: If the new crite-
ria are applied, the number of subjects who fulfill the reimbursement criteria in the 
high risk group will be almost twice as many as before. This would lead to an great 
increase in the NHI expenditures for statins and monitoring costs, however, this 
could be offset by the treatment cost saved from the averted CHD and stroke cases. 
Therefore, the new criteria are a dominant strategy compared with the original cri-
teria. ConClusions: Although the newly proposed reimbursement criteria would 
lead to an increase in drug expenditure of NHIA, it is expected to be a cost-saving 
strategy after taking into account the health benefit on preventing CHD and stroke.
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objeCtives: The current study primarily aimed to assess the current prescribing 
pattern of lipid-lowering agents and the percentage of LDL-C goal attainment in 
myocardial infarction (MI) patients in local practice, and to evaluate clinical out-
comes of patients stratified by prescription of statins and by LDL-C level attained 
after discharge. Methods: We retrospectively reviewed 696 hospitalized patients 
in the local ACS registry of Prince of Wales Hospital during 1 January 2008 to 31 
December 2009 with data retrieved using computerized clinical records of all 
patients. Results: Among the 402 MI patients included, 104 (25.9%) were not pre-
scribed with statins at discharge. Percutaneous coronary intervention (PCI) per-
formed or planned during hospitalization (OR: 0.324, p= 0.001) and latest LDL-C level 
before discharge (OR: 0.221 for an increment of 1 mmol/L, p= 0.009) were significant 
independent predictors of the absence of statin prescriptions at discharge. A sig-
